Is lurbinectedin linked to birth defects?
Yes, lurbinectedin (brand name Zepzelca) carries warnings for potential birth abnormalities due to its genotoxic properties as an alkylating-like agent that damages DNA. Animal studies show embryo-fetal toxicity, including malformations and reduced fetal growth, at doses below human equivalents. Human data is limited, but the drug is pregnancy category not assigned (high risk); it's contraindicated in pregnancy, with recommendations for contraception during treatment and for 6 months after in females of reproductive potential (4 months in males).[1][2]
What do FDA labels and prescribing info say?
The Zepzelca label states: "Based on its mechanism of action and findings from animal studies, Zepzelca can cause fetal harm when administered to a pregnant woman." Embryo-fetal development studies in rats and rabbits revealed post-implantation loss, malformations (e.g., anasarca, cleft palate), and skeletal abnormalities. No adequate human pregnancy data exists, but genotoxicity tests (e.g., chromosomal aberrations) confirm risks.[1]
How does it compare to similar chemotherapy drugs?
Like other alkylating agents (e.g., cyclophosphamide), lurbinectedin inhibits cell division, posing high teratogenic risk during organogenesis. Unlike some targeted therapies, it lacks extensive human safety data in pregnancy, aligning more with traditional cytotoxics flagged for congenital anomalies.[2][3]
What precautions do doctors recommend?
Verify pregnancy status before starting; use effective non-hormonal contraception. Patients must enroll in a REMS-like program if applicable. Report exposures via FDA's pregnancy registry. Breastfeeding is not advised due to excretion risks.[1]
Are there real-world cases or clinical trial data?
No published human cases of birth defects from lurbinectedin monotherapy, as trials excluded pregnant patients. Post-marketing surveillance is ongoing, but its 2020 approval limits long-term data. Analogous drugs show 10-50% malformation rates in exposed pregnancies.[2]
[1]: FDA Zepzelca Label
[2]: Drugs.com - Lurbinectedin Pregnancy
[3]: PubMed - Genotoxicity of Lurbinectedin